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Abstract: Recent research has spotlighted the role of microRNAs (miRNAs) as critical 
epigenetic regulators of hematopoietic stem cell differentiation and leukemia development. 
Despite the recent advances in knowledge surrounding epigenetics and leukemia, the 
mechanisms underlying miRNAs’ influence on leukemia development have yet to be 
clearly elucidated. Our aim was to identify high ranking biological pathways altered at the 
gene expression level and under epigenetic control. Specifically, we set out to test the 
hypothesis that miRNAs dysregulated in acute myeloid leukemia (AML) converge on a 
common pathway that can influence signaling related to hematopoiesis and leukemia 
development. We identified genes altered in AML patients that are under common 
regulation of seven key miRNAs. By mapping these genes to a global interaction network, 
we identified the “AML Signalisome”. The AML Signalisome comprises   
53 AML-associated molecules, and is enriched for proteins that play a role in the aryl 
hydrocarbon receptor (AhR) pathway, a major regulator of hematopoiesis. Furthermore, 
we show biological enrichment for hematopoiesis-related proteins within the AML 
Signalisome. These findings provide important insight into miRNA-regulated pathways in 
leukemia, and may help to prioritize targets for disease prevention and treatment. 
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1. Introduction 
In the past decade, microRNAs (miRNAs) have emerged as major players in cellular regulation, 
especially related to carcinogenesis. The expression profiles of miRNAs can be used to classify tumor 
types and tumor differentiation state with high levels of accuracy [1]. Hematological malignancies,  
in particular, are considered to be largely influenced by miRNAs. For example, miRNAs are known to 
regulate hematopoietic stem and/or progenitor cell differentiation [2]. Bone marrow cells from 
leukemia patients also show significantly altered miRNA expression profiles, where miRNAs related 
to hematopoiesis are some of the most consistently dysregulated miRNAs in leukemia [3,4].   
Because of their role in leukemogenesis, miRNAs are also considered promising therapeutic targets for 
new leukemia treatment strategies [4]. 
1.1. miRNA Background 
The first miRNA was discovered in Caenorhabditis elegans in 1993 [5]. In 2001 miRNAs received 
a high level of interest, when they were first reported to act as gene silencers [6,7]. Now seen as 
important epigenetic regulators, miRNAs play a key regulatory role in mRNA abundance and protein 
production [8]. By base pairing to target mRNAs, miRNAs can cause mRNA degradation and/or 
translational repression [9]. Current estimates suggest that mammalian miRNAs regulate more than 
60% of all protein-coding genes [10]. Because miRNAs play such pivotal roles in gene regulation, it is 
important to understand the relationship of miRNAs with disease. 
1.2. Acute Myeloid Leukemia (AML) Background 
Research involving epigenetics has recently focused on the study of cancers with high prevalence 
and/or mortality rates. For example, leukemia is prevalent in the United States, where it is estimated 
that 1 in 75 people will be diagnosed during their lifetime [11]. Acute myeloid leukemia (AML) is one 
of the most common types of leukemia among adults [11]. AML is characterized as a clonal disorder 
of hematopoietic progenitor cells which have lost the ability to differentiate normally and respond to 
regulators of proliferation or pro-apoptotic signals [12]. These changes result in the accumulation of 
progenitor cells arrested at various stages of development, which can eventually lead to fatal infection, 
bleeding, or organ infiltration [12]. 
1.3. Pathways Modulated in Leukemia 
The mechanisms underlying leukemogenesis often involve changes in cellular signaling, which can 
inhibit hematopoietic progenitor cells from: (i) responding to normal signals regulating proliferation, 
and/or (ii) differentiating into mature red blood cells, monocytes, neutrophils, and platelets [12]. Many 
pathways have been shown to be altered in AML blood and bone marrow cells, including the nuclear Int. J. Environ. Res. Public Health 2012, 9   1941 
 
factor kappa-B (NFκB) [13], mitogen-activated protein kinase (MAPK) [14], and Wnt/β-catenin 
pathways [15]. The aryl hydrocarbon receptor (AhR) pathway is also implicated in leukemogenesis [16], 
where, for example, primary human T-cell leukemia cells have shown up-regulated AhR expression 
and activation [17]. Furthermore, dysregulated AhR signaling within hematopoietic stem cells has 
been proposed as a possible mechanism linking benzene exposure to AML development [18]. 
1.4. Previous Studies on miRNAs in AML 
Since the initial miRNA tumor classification studies [1], many other researchers have investigated 
miRNAs and their involvement in AML. For example, numerous studies have correlated miRNA 
expression levels to cytogenetics in AML patients with the goal of identifying diagnostic and 
prognostic indicators, as reviewed by Marcucci et al. [3]. Some studies have also correlated the 
expression levels of individual miRNAs with genome-wide mRNA expression levels, and identified 
subsets of genes likely regulated by individual miRNAs in AML. In cytogenetically normal AML 
patients, for example, miR-181a expression levels have been shown to inversely correlate with the 
expression of genes involved in innate immunity [19]. 
1.5. Study Aim 
We hypothesize that miRNAs likely act in a concert to exert their biological functions.   
More specifically, we propose that the coordinated action of miRNAs on their transcriptional targets 
may influence key biological pathways involved in leukemogenesis. A recent paper [20] in which the 
role of multiple miRNAs on transcriptional regulation has been shown supports this hypothesis. What 
remains to be identified is whether a key biological pathway may be the target of such concerted 
miRNA control. Our study addresses this issue using a novel analytical strategy to compare 
epigenetically-regulated signaling within AML cells versus non-leukemia cells. 
While previous studies have identified associations between individual miRNAs and leukemia-related 
gene expression profiles, we employed a systems-level approach to identify converging pathways 
regulated by several key AML-associated miRNAs. We predicted that the statistical integration of 
existing databases, along with systems-level pathway analyses, would reveal high ranking biological 
pathways altered at both the gene expression and epigenetic (e.g., miRNA) level in AML patients. Thus, 
this study’s goal was to elucidate novel biological relationships that may underlie leukemogenesis. 
2. Methods 
2.1. Identifying the AML-Associated Gene Expression Signature 
In order to identify a genomic signature associated with AML, we performed a statistical analysis 
comparing gene expression levels between AML patients and non-leukemic individuals. Specifically,  
a publically available database containing microarray data from patients with AML (n = 202), 
myelodysplastic syndrome (n = 164), or from non-leukemic, control patients (n = 69) was downloaded 
from the National Center for Biotechnology Information’s Gene Expression Omnibus [21]. This 
dataset was generated in an investigation by Mills et al., where microarray-based classifiers were 
identified to predict the risk of AML transformation in patients with myelodysplastic syndrome [22]. Int. J. Environ. Res. Public Health 2012, 9   1942 
 
Of the 202 AML patients, 21 were categorized with complex aberrant karyotype, while 181 were 
categorized with normal karyotype or other abnormalities. This differential karyotype was included in 
the subsequent analysis. To note, all samples were obtained from untreated patients at the time of 
diagnosis, as part of the collaborative Microarray Innovations in Leukemia (MILE) study [22,23]. 
Total RNA from bone marrow mononuclear cells was extracted and hybridized to microarrays,  
as described previously [22,24]. Gene expression data derived from probe set intensity signals from  
202 AML and 69 non-leukemic patients were used. To identify genes that were differentially 
expressed in AML patients, statistical analyses were performed as follows. Data were filtered for 
removal of background (<abs [100]) in 20% of the samples. Differential expression was defined as a 
significant difference in transcript levels between AML versus non-leukemic patients, where three 
statistical requirements were set: (i) a fold change of ≥2.5 or ≤−2.5 (AML versus non-leukemic);  
(ii) p value <0.01 (ANOVA); and (iii) a false discovery rate corrected q-value <0.01. Analysis of 
variance (ANOVA) p values were calculated using Partek
® Genomics Suite
TM software,   
version 6.5 [25]. To control the rate of false positives, q-values were calculated as the minimum 
“positive false discovery rate” that can occur when identifying significant hypotheses [26].   
This criteria was set based on our published methods [27,28], where statistical stringency is employed 
to allow the identification of genes significantly associated with disease status, while allowing minimal 
false positives. The genes that met these statistical requirements were identified as significantly 
differentially expressed in AML patients, and represent the AML-associated gene expression signature. 
2.2. Identifying AML-Associated miRNAs and Their Transcriptional Targets 
A set of miRNAs modulated in AML patients was identified through an extensive literature review. 
The miRNAs were selected based on their altered expression levels in AML versus normal cells and 
their relevance to leukemia development. The studies included were Bousquet et al. [29],   
Cammarata et al. [30], Garzon et al. [31], Han et al. [32], O’Connell et al. [33], and Wang et al. [34]. 
In order to understand the effects that the AML-associated miRNAs (n = 7) may cause at the gene 
expression level, computational predictions of the transcriptional targets of the AML-associated 
miRNAs were carried out. Here, TargetScanHuman [35] algorithms were employed to identify 
potential matches between the 3’-untranslated mRNA regions and miRNA seed sequences for each of 
the miRNAs [36]. The resulting predicted miRNA-mRNA interactions were filtered for the probability 
of preferentially conserved targeting (PCT) ≥0.5. This PCT filter controlled for background conservation 
across mammals by accounting for mutational biases, dinucleotide conservation rates, and individual 
untranslated region conservation rates [10]. 
2.3. Network, Pathway, and Functional Enrichment Analysis 
Network analysis was performed to identify biological pathways that are targets for miRNA-mediated 
control in AML. For this analysis, a list of AML-associated genes predicted to be targeted by at least 
one of the AML-associated miRNAs was overlaid onto a global interaction network. Networks were 
algorithmically constructed based on connectivity, as enabled through Ingenuity Pathway   
Analysis [37]. Canonical pathways within the constructed networks were then identified.   
Over-represented pathways were defined as pathways that contain more AML-associated genes than Int. J. Environ. Res. Public Health 2012, 9   1943 
 
expected by random chance, as calculated using the right-tailed Fisher’s Exact Test. Pathways with 
enrichment p values <0.05 were considered significant. In a similar fashion, functional enrichment 
analysis was performed to identify biological functions and disease signatures significantly associated 
with the AML-associated gene signature predicted to be regulated by AML-associated miRNAs. 
Significance was calculated in the same manner as the pathway enrichment analysis, where functions 
with enrichment p values <0.0001 were considered significant. 
3. Results 
3.1. Identifying the AML Signalisome 
In this study, we predicted that miRNAs act together to control genomic signaling of biological 
pathways associated with AML. To test this hypothesis, we analyzed genomic data from individuals 
with or without AML, and integrated the genomic data with miRNAs and their transcriptional targets 
in a six step process (Figure 1). Through this process we uncovered for the first time an AML network, 
or Signalisome, that is regulated by multiple miRNAs. 
Figure 1. Steps in identifying the AML Signalisome. 
 
3.1.1. AML-Associated Gene Expression Signature Is Identified 
To identify a set of genes differentially expressed in AML patients relative to non-leukemic 
patients, we performed a statistical analysis using publically available data. Data from Mills et al. [22] 
were used in a new manner to compare the genome-wide expression levels between 202 AML patients 
and 69 non-leukemic patients. Statistical analysis revealed 731 genes (represented by 1,119 probe sets) 
that were significantly differentially expressed in bone marrow mononuclear cell samples from   
AML versus non-leukemic patients (Figure 2; see electronic supplementary information, Table S1). As 
the samples were collected at the time of diagnosis for patients enrolling in the MILE study, this 
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genomic signature represents a baseline state and is not confounded by treatment. This gene list was 
used as the AML-associated gene expression signature throughout the remaining analyses. 
Interestingly, several of the AML-associated genes overlapped with those highlighted in the Mills et al. 
report [22] and are involved in AML progression, including fms-related tyrosine kinase 3 (FLT3), v-kit 
Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT), runt-related transcription factor 1 
(RUNX1), and Wilms tumor 1 (WT1). 
Figure 2. Heat map displaying the relative expression levels of the 731 AML-associated 
genes. Expression levels are z-score normalized. 
 
A comparison between the AML-associated gene signature and a previously published set of   
AML-related genes was also performed. The gene set to which we compared the AML-associated gene 
expression signature consisted of 66 genes that have been identified as accurate predictors of overall 
survival for AML patients [38]. Given the difference in study designs, the degree of overlap between 
the gene signatures is robust. Specifically, a total of 24 of the 66 genes (36%) identified as predictors 
of survival in AML patients were also present in our AML-associated gene signature (see electronic 
supplementary information, Table S2). 
3.1.2. AML-Associated miRNAs Are Identified 
Based on previous studies that have highlighted the changes in sets of miRNAs, we hypothesized 
that miRNAs likely act in a coordinated manner to mediate their regulatory effects through key 
biological pathways. Thus to identify miRNAs known to be altered in expression in AML patients,  
a thorough literature review was conducted. A total of seven AML-associated miRNAs were 
identified, consisting of miRNAs with significant differential expression in blood and/or bone marrow 
samples collected from AML patients in comparison to non-leukemic patients. To detail, miR-125b, 
miR-126, miR-142-3p, miR-155, miR-223, miR-29a, and miR-29b have all shown altered expression 
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levels in AML samples versus non-leukemic samples [29–34] (Table 1). Furthermore, all of these 
miRNAs are suggested to play roles in leukemogenesis [32,33,39–44]. 
Table 1. AML-associated miRNA database. 
miRNA 
Reference(s) for Differential 
Expression in AML Patients 
Reference(s) for Suggested 
Role in Leukemogenesis 
miR-125b  [29]  [39] 
miR-126  [30,31]  [40] 
miR-142-3p  [34]  [41] 
miR-155  [31,33]  [33] 
miR-223  [30]  [42,44] 
miR-29a  [30,32,34] [32] 
miR-29b  [31]  [43] 
3.1.3. miRNA-Regulated Genes Are Predicted 
To understand genomic changes that occur in AML patients likely via changes in miRNA 
expression, we computationally predicted transcriptional targets of the seven AML-associated 
miRNAs. Using seed match-based algorithms, 196 genes were predicted to be targeted by miR-125b, 
22 by miR-126, 308 by miR-142-3p, 164 by miR-155, 68 by miR-223, 805 by miR-29a, and 179 by 
miR-29b. In total, 1,589 unique genes were predicted to be targeted by at least one of the seven  
AML-associated miRNAs (see electronic supplementary information, Table S3). 
3.1.4. The miRNA-Mediated AML Gene Signature Is Identified 
With the goal of identifying genes with altered expression levels in AML that are likely regulated 
by miRNAs, we compared the 731 genes of the AML-associated gene expression signature (identified 
in step 1 of the analysis) to the 1,589 genes predicted to be targeted by AML-associated miRNAs 
(identified in step 3 of the analysis). This comparison showed that 78 genes contained in the   
AML-associated gene signature are likely regulated by AML-associated miRNAs (see electronic 
supplementary information, Table S4). 
3.1.5. The AML Signalisome Is Identified 
In order to identify whether the miRNA-mediated genomic changes occur in the context of high 
level interactions, molecular networks were constructed using the 78 AML-associated genes that were 
predicted to be regulated by the AML-associated miRNAs. A total of five significant (p value < 0.01) 
sub-networks were constructed (see electronic supplementary information, Table S5). Interestingly, 
four of the five sub-networks interact, which when combined, form the AML Signalisome (Figure 3).  
This AML Signalisome consists of 133 proteins, 53 of which are encoded by genes altered in AML 
and predicted to be targeted by AML-associated miRNAs. 
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Figure 3. The AML Signalisome. Proteins encoded by genes dysregulated in AML 
patients are shaded in colors corresponding to their regulatory miRNA(s). White molecules 
are associated with the AML-associated genes. 
 
3.1.6. Members of the AhR Pathway Are Enriched within the AML Signalisome 
Our study set out to identify high ranking biological pathways altered at the gene expression level 
and likely regulated by miRNAs in AML patients. Through pathway enrichment analysis, we identified 
six canonical pathways that are significantly enriched within the AML Signalisome (Table 2). 
Biologically, these six pathways represent well-characterized metabolic and cell signaling pathways 
that are enriched among proteins encoded by AML-associated genes likely regulated by miRNAs.  
The most significant pathway within the AML Signalisome is the aryl hydrocarbon receptor (AhR) 
signaling pathway (p = 0.017). AhR pathway signaling is also present in the most significant   
(p < 10
−44) sub-network within the AML Signalisome (Figure 4). In addition, we analyzed genes 
identified as AML-associated after exclusion of gene expression obtained from patients with an 
aberrant karyotype (n = 21). Indeed, the identification of the enrichment of genes that play a role in the 
AhR pathway was independent of the exclusion of aberrant karyotype samples (data not shown). 
To further establish the biological relevance of our findings, we performed a biological function and 
disease signature enrichment analysis. Here, 18 functions or disease signatures were identified as 
significantly associated with the AML Signalisome (see electronic supplementary information,   
Table S6). Of note, the four most significant functions or disease signatures were cellular development 
(p = 1 × 10
−6), cancer (p = 3 × 10
−6), hematological system development and function (p = 3 × 10
−6), 
and hematopoiesis (p = 3 × 10
−6). 
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Table 2. Canonical pathways enriched within the AML Signalisome. 
Pathway  p value 
Aryl Hydrocarbon Receptor Signaling  0.017 
Hepatic Fibrosis/Hepatic Stellate Cell Activation  0.019 
Airway Pathology in Chronic Obstructive Pulmonary Disease  0.032 
Calcium Signaling  0.032 
Aminosugars Metabolism  0.032 
HER-2 Signaling in Breast Cancer  0.038 
Figure 4. AhR-related signaling molecules are enriched within the AML Signalisome. 
 
4. Discussion 
In this study, we set out to identify key biological pathways that are under concerted   
miRNA-mediated regulation in AML patients. Specifically, we hypothesized that miRNAs likely act 
together to control pathway signaling related to hematopoiesis and leukemia development. Previous 
studies have evaluated the influence of individual miRNAs on gene expression signatures present in 
AML cells [43,45,46]. However, there is a paucity of data regarding AML-associated genomic 
signatures and altered pathways that are regulated through the combined effects of multiple miRNAs. 
Our study aimed to fill this knowledge gap by performing statistical analyses on genomic databases, 
predicting miRNA-mRNA interactions, and constructing molecular networks likely regulated by 
multiple miRNAs in AML patients. 
The first step in our analysis was to identify an AML-associated gene expression signature.   
Here, publicly available data containing gene expression microarray data from 271 patients’ bone 
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marrow mononuclear cell samples [22] were statistically assessed. Of the 202 AML patients used in 
this study, 90% of them were described as having normal karyotype. Using stringent statistical 
parameters, we identified an AML-associated gene signature consisting of 731 genes altered in AML 
patients in comparison to non-leukemic individuals. Not surprisingly, many of the genes within the 
AML-associated gene signature have known involvement in AML disease progression. For example, 
several of the AML-associated genes have been recognized previously for their involvement in AML 
progression, including FLT3, KIT, RUNX1, and WT1 [22]. In addition, a gene set of 66 genes has been 
identified as an accurate predictor of overall survival in AML patients [38]. Of these 66 genes,   
24 (36%) are present in our AML-associated gene signature. 
In order to understand epigenetic regulation in leukemia, we next identified miRNAs that are 
dysregulated in AML patients and predicted their transcriptional targets. Here, miRNAs were selected 
if they have shown significant differential expression in AML versus non-leukemic blood or bone 
marrow samples. In addition, the AML-associated miRNAs were required to have suggested roles in 
leukemogenesis. With these criteria, seven miRNAs were selected as AML-associated miRNAs:   
miR-125b, miR-126, miR-142-3p, miR-155, miR-223, miR-29a, and miR-29b. Seed match-based 
algorithms were then employed to predict 1589 genes regulated by the miRNAs. Of the 1,589 
predicted genes, 78 were also within the AML-associated gene signature. Therefore, we find that 78 of 
the 731 genes (10.7%) with altered expression levels in AML patients are likely targets of the seven 
key AML-associated miRNAs. 
The percentage of genes likely regulated by AML-associated genes may seem low, as mammalian 
miRNAs are estimated to regulate more than 60% of all protein-coding genes [10]. Furthermore, 
ectopic transfection of miR-29a and miR-29b has been associated with the altered expression levels of 
572 and 480 genes, respectively, in myeloid leukemia cells [43]. However, these analyses were highly 
focused and limited to the role of seven miRNAs in the transcriptional response. Thus, the finding is in 
line with the analytical strategy we employed. 
We set out to determine whether the miRNA-regulated AML-associated genes interact and 
uncovered the AML Signalisome. This AML Signalisome was identified based on molecular 
interactions between proteins encoded by the 78 genes within the miRNA-mediated AML gene 
signature. The resulting AML Signalisome includes network interactions of molecules whose 
transcription are altered in AML cells. The AML Signalisome clearly illustrates that molecular 
signaling altered in AML cells is likely influenced by the coordinated actions of multiple miRNAs 
acting on common pathways. This finding provides novel evidence supporting our prediction that 
miRNAs likely act together to regulate important pathways altered in AML cells. 
Within the AML Signalisome, there is a significant enrichment for genes involved in   
AhR signaling, as well as functional enrichment for cellular development, cancer, hematological 
system development/function, and hematopoiesis. In particular, all seven AML-associated miRNAs,  
miR-125b, miR-126, miR-142-3p, miR-155, miR-223, miR-29a, and miR-29b, were predicted to 
regulate the most significant sub-network within the AML Signalisome containing AhR pathway 
signaling. Interestingly, the AhR pathway is known to play a major role in the regulation of 
hematopoiesis, where altered AhR signaling can contribute to hematological disorders, including 
leukemia [16]. Although the exact mechanisms by which AhR regulates hematopoietic stem cell 
function or number are unknown, some plausible mechanisms have been proposed [16]. One of the Int. J. Environ. Res. Public Health 2012, 9   1949 
 
proposed mechanisms involves altered AhR levels and/or activation, leading to altered expression of 
AhR-regulated genes. The resulting transcriptional dysregulation may cause blocked differentiation of 
hematopoietic stem cells and the accumulation of progenitor stem cells [16]. Alternative mechanisms 
linking altered AhR signaling to leukemogenesis may also exist [16].  
Altered AhR signaling, potentially regulated via AML-associated miRNAs, is of high significance 
and may represent a key mechanism potentially underlying leukemogenesis. It is important to note that 
the AhR pathway is a key regulator of stress and xenobiotic response [47]. As such, the AhR pathway 
could be influenced by chemotherapeutic treatment. In our study, the dysregulation of the AhR 
pathway is clearly disease-associated, as the genomic profiles used to study systems-level interactions 
were abstracted from AML samples collected at time of diagnosis and not post-treatment. Interestingly,  
a study on another epigenetic regulator, cytosine DNA methylation, showed that the AHR promoter 
region is frequently hypermethylated in acute lymphoblastic leukemia [48]. To our knowledge, this is 
the first study to identify the AhR pathway as potentially dysregulated and under the control of 
multiple miRNAs in leukemia patients. 
Other pathways besides AhR signaling have been identified as altered through miRNA regulation in 
AML. For example, miR-29b has been shown to influence signaling related to NFκB, Sp1 
transcription factor (SP1), and histone deacetylase (HDAC) [45]. In addition, the nuclear factor 
[erythroid-derived 2]-like 2 (NRF2), tumor necrosis factor-α (TNF), and heme oxygenase-1 (HO-1) 
have all been shown to be influenced by miRNAs in AML cells, and have been suggested to play a 
role in AML chemo-resistance [4]. Our results do not highlight these previously identified interactions 
for several potential reasons. For instance, we require the influence of multiple miRNAs instead of just 
a single miRNA, unlike most other related investigations. In addition, our AML-associated gene 
expression signature was identified through a comparison of AML patients and non-leukemic patients. 
Most other studies compare only within AML subtypes. Lastly, studies investigating miRNA 
regulation in AML are currently lacking systems biology-based analyses, making it difficult to 
compare our results to previous research on pathway modifications. Future research should focus on 
molecular pathways altered at the epigenetic level in AML. 
Our study assessed miRNA-mediated pathway interactions that are altered in AML patients.   
We identified that multiple miRNAs likely act together to regulate key biological pathways altered in 
AML. The implications of this finding suggest that AML targeted therapies focusing on single 
miRNAs may prove ineffective in some cases. Our data suggests that targeting of multiple miRNAs or 
their downstream pathways may be more effective. Future research will further evaluate transcriptomic 
changes induced by multiple AML-associated miRNAs, while considering AML patient subtypes as 
well as potential cytogenetic abnormalities. Understanding the epigenetically modified pathways 
underlying AML progression is extremely important, as increased pathophysiological understanding 
will foster the development of new effective therapies. 
5. Conclusions 
We used a systems-level approach to identify AML-associated biological pathways targeted for 
transcriptional control by a set of miRNAs. We found that AML-associated transcripts targeted by 
critical miRNAs interact in a highly significant manner. These interactions, when combined, form the Int. J. Environ. Res. Public Health 2012, 9   1950 
 
AML Signalisome. Within this AML Signalisome, there is a significant enrichment for proteins of the 
AhR pathway and within hematopoiesis-related functions. These findings have implications for 
understanding biological pathways perturbed in disease that may inform targeted therapeutic strategy. 
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